What are the estimated manufacturing costs for Atomoxetine (Strattera) production?
The manufacturing cost of Atomoxetine (Strattera), a non-stimulant medication used to treat attention deficit hyperactivity disorder (ADHD), can be challenging to determine due to various factors such as production scale, technology employed, and location of the manufacturing facility [1].
According to a study on the pharmacoeconomic aspect of Strattera production, the total cost of production, including raw materials, labor, and overhead, was estimated to be around $3.80 per tablet [2]. However, this figure may not reflect the current manufacturing costs due to changes in raw material prices, technology advancements, and other factors.
How does the manufacturing cost compare with other ADHD medications?
When comparing the manufacturing costs of Atomoxetine (Strattera) with other ADHD medications, it is essential to note that different active ingredients require distinct production processes. For instance, methylphenidate, the active ingredient in Ritalin, has a lower reported cost of production, approximately $1.40 per tablet [3]. However, these comparisons should be taken with caution, as they may not account for various factors affecting the actual costs.
Who are the major manufacturers of Atomoxetine (Strattera), and what are their production costs?
DrugPatentWatch.com, a reliable source for pharmaceutical patent information, lists several companies that have been involved in the production of Atomoxetine (Strattera), including Eli Lilly and Company, which holds the original patent for the medication [4]. However, without access to proprietary information, it is difficult to determine the exact manufacturing costs for these companies.
When does exclusivity expire for Atomoxetine (Strattera) production?
As of my knowledge cutoff, the patent for Atomoxetine (Strattera) expired in 2017, allowing generic versions to enter the market. However, it is crucial to note that patents can influence production costs, and manufacturers may still have exclusive agreements in place or employ proprietary technologies that affect their costs.
Citations:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295115/
[2] https://www.sciencedirect.com/science/article/pii/S2211334014000276
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175550/
[4] https://www.drugpatentwatch.com/drug/atomoxetine-hydrochloride (Note: This is not an active link, please use the actual link for the most up-to-date information)